Research & Education

IASLC European Webinar Series - 2015/2016 - Maintenance Therapy in Advanced Non-Small Cell Lung Cancer

Wednesday, February 10, 2016 - 7 p.m. CET - Recording Available

In patients with metastasized non-small-cell lung cancer (NSCLC) the current typical first-line treatment approaches are four cycles cisplatin and pemetrexed in patients with non-squamous cell carcinoma. As an alternative, centers still administer carboplatin, paclitaxel and bevacizumab and these are given for four to six cycles. Strategies of maintenance chemotherapy include "switch maintenance" with changing from four cycles carbo/pacli/bev or other non-pemetrexed combinations to maintenance pemetrexed until the time of progression and "continuation maintenance" with keeping single agent pemetrexed as ongoing treatment following four cycles of cisplatin and pemetrexed. Both strategies have been shown in large prospectively randomized phase-III trials (JMEN, PARAMOUNT) to significantly improve median overall survival at about three months as well as double the median PFS at very little costs of toxicity. This strategy has since become an important option to patients for the management armamentatium of metastasized non-small-cell lung cancer without any druggable driver mutation.

Taking Bites of the KRAS Pie: Co-occurring mutations define KRAS subsets with distinct biology, immune profiles, and drug vulnerabilities

Wednesday, January 27, 2016 at 9 p.m. EST - Recording Available

IASLC continues the Lung Cancer Series in 2016 with this LIVE WEBINAR featuring Dr. John Heymach.

KRAS is the most common oncogenic driver in non-small cell lung cancer and other solid tumors. Despite great rapid recent progress in the treatment other oncogene-driven malignancies, to date there are still no targeted therapies for KRAS mutant lung cancers. A major obstacle to progress in this area is the heterogeneity among different KRAS tumors. Here, we discuss how co-occurring genomic alterations impact KRAS signaling and define distinct KRAS subgroups with different drug response patterns and immune profiles, and how such an understanding of Kras subsets can lead to development of more refined therapeutic approaches.

IASLC European Webinar Series - 2015/2016 - Advances in Radiotherapy for Lung Cancer

Wednesday, January 20, 2016 - 6:30 p.m. CET - Recording Available

Radiotherapy for lung cancer is rapidly changing. Today, stereotactic irradiation (SBRT) is recognized as a safe and efficient treatment technique for smaller lung tumors (NSCLC). The approach to centrally located tumors is more controversial. In advanced-stage III disease, several large clinical trials have attempted to address the optimal incorporation of chemotherapy and radiotherapy for stage III disease.

IASLC European Webinar Series - 2015/2016 - Immunotherapy for Lung Cancer 2016

Wednesday, January 13, 2016 - 4 p.m. GMT - Recording Available

Recent approvals of anti-PD-L1 agents for the second- and subsequent line of treatment of non-small cell lung cancer, as well emerging data with agents under active clinical evaluation mark a new era in the management of lung cancer.

New Frontiers in the Management of Lung Cancer

Thursday, January 7, 2016 at 6 p.m. HKT - Recording Available

In this 60-minute session, this expert faculty will address the latest clinical developments and evolving standards impacting the management of advanced stage non-small cell lung cancer (NSCLC). This will be an interactive event and attendees can e-mail their questions and comments to the faculty for fruitful exchange.

Management of Locally Recurrent NSCLC Following SBRT

Wednesday, December 9, 2015 at 8 p.m. JST - Recording Available

The IASLC Education Committee is pleased to announce the fourth program in the 2015 series of Live Webinars presented by the Advanced Radiation Therapy (ART) Committee. This subcommittee is focused on the development and execution of educational and informational programs addressing state of the art radiation therapy for lung cancer.

EGFR TKI Therapy for Advanced Stage NSCLC: Patient Selection and Treatment Options

Tuesday, December 8, 2015 at 9 p.m. EST - Recording Available

IASLC continues the Lung Cancer Grand Round Series in 2015 with this LIVE WEBINAR featuring Dr. Anne Tsao.

This program will review the role of EGFR tyrosine kinase inhibitors (TKI) in EGFR mutated NSCLC. The most common types of EGFR mutations and their clinical outcomes/sensitivity to EGFR TKIs will be evaluated. A discussion on the use of frontline EGFR TKIs versus maintenance therapy in this population will be undertaken.

Challenging Cases in Early-Stage NSCLC

Wednesday, November 18, 2015 at 9 p.m. EST - Recording Available

IASLC continues the Lung Cancer Grand Round Series in 2015 with this LIVE WEBINAR featuring Dr. Heather Wakelee.

This presentation will focus on highlights from recently presented large adjuvant trials including RADIANT, SCAT, ITACA and E1505. It will address different chemotherapy options for the adjuvant treatment of resected early stage NSCLC and review key ongoing trials looking to advance the adjuvant therapy of patients with resected NSCLC.

IASLC European Webinar Series - 2015/2016 - Lung Cancer in Women

Tuesday, November 10, 2015 - 7 p.m. CET - Recording Available

For several decades, lung cancer has been considered a neoplastic disease affecting mainly men; however, during the past 40 years, the incidence of the disease has increased exponentially among women. Dr. Silvia Novello will cover epidemiologic changer regarding gender and lung cancer; smoking habit as the first risk factor for lung cancer also in women; lung cancer in never smokers and gender issues and present an overview on steroid hormones role in gender differences for lung cancer and other factors.

Best of 2015 World Conference on Lung Cancer (WCLC)

Wednesday, October 21, 2015 at 9 p.m. EDT - Recording Available

IASLC continues the Lung Cancer Grand Round Series in 2015 with this LIVE WEBINAR featuring Dr. Suresh Ramalingam.

Dr. Ramalingam will identify and discuss the key abstracts, presentations and developments reported during the recent IASLC World Conference on Lung Cancer held September 2015.

Pages